StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for KALA yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $2.90 | $2.71 | -6.55% | 0.1M |
| 05-19 | $2.78 | $2.53 | -8.99% | 0.1M |
| 05-20 | $2.61 | $2.65 | +1.53% | 0.1M |
| 05-21 | $2.67 | $2.60 | -2.62% | 0.1M |
| 05-22 | $2.61 | $2.43 | -6.90% | 0.1M |
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $3.89M |
Operating Income | $-39.16M | $-40.98M | $-39.66M | $-81.71M |
Net Income | $-26.98M | $-38.51M | $-42.20M | $-44.82M |
EPS (Diluted) | $-3.31 | $-10.15 | $-17.35 | $-29.48 |
Total Assets | $9.49M | $55.48M | $55.95M | $86.82M |
Total Liabilities | $2.49M | $43.15M | $48.45M | $67.85M |
Cash & Equivalents | $7.56M | $51.18M | $50.90M | $70.50M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 557.00K | 6.09M | 2.76M | 1.71M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.